Aeras awarded €11.7 million ($16 million) grant from Dutch government
This expression of support represents a continuation in the long-standing collaboration between the Dutch government, Aeras and its research partners. This is the second grant to Aeras from the Netherlands Ministry of Foreign Affairs, representing a total commitment of €30.4 million to Aeras since 2006.
"The forward movement of TB vaccine candidates in the development pipeline owes a great deal to the generous support of the Dutch Ministry of Foreign Affairs and the people of the Netherlands," said Jim Connolly, President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation. "We are extraordinarily grateful for their foresight and steadfast support of these potentially life saving efforts."
New TB vaccines are urgently needed. The currently available vaccine, Bacille Calmette-Guérin, provides some protection against pediatric TB but is unreliable in protecting adult pulmonary TB, the most common form of the disease. As a product development partnership, Aeras collaborates and facilitates research in conjunction with numerous scientists in academic, pharmaceutical, biotechnology and government research centers around the world to develop safer and more immunogenic TB vaccines. Globally, nine TB vaccine candidates are currently undergoing clinical testing, and of those, four are directly supported and led by Aeras and its network.
Since the Netherlands's first grant to Aeras and its partners in 2006, four TB vaccine candidates in Aeras' product portfolio have moved into clinical testing in Europe, North America and Africa. Two of those are at the Phase II proof of concept stage and will enroll infants in South Africa, Kenya, Uganda and Mozambique.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.